Brief: Kronos Bio Announces Selection Of Recommended Phase 2 Dose For Oral CDK9 Inhibitor, KB-0742
07/12/2022 21:10
Dec 7 (Reuters) - Kronos Bio Inc KRON.O :
* KRONOS BIO ANNOUNCES SELECTION OF RECOMMENDED PHASE 2 DOSE
FOR
ITS ORAL CDK9 INHIBITOR, KB-0742, AFTER REACHING TARGET
ENGAGEMENT GOAL WITH ACCEPTABLE SAFETY PROFILE IN ONGOING PHASE
1/2 CLINICAL TRIAL
* KRONOS BIO INC- 60 MG DOSE APPEARS TO HAVE AN ACCEPTABLE
SAFETY
PROFILE
* KRONOS BIO INC- WILL ENROLL TWO COHORTS OF PATIENTS IN
THIS
PHASE 2 STAGE OF STUDY
Source text for Eikon: ID:nGNX9k3Zfw
Further company coverage: KRON.O
Recent news on Kronos Bio
See all newsBrief: Kronos Bio Inc - Terminates Office Lease At 301 Binney Street - SEC Filing
Brief: Kronos Bio Inc - Enters Transition Agreement With Genentech
U.S. STOCKS ON THE MOVE - Ambarella, Dell, Nordstrom
U.S. STOCKS ON THE MOVE - Golden Ocean, Guess, Symbotic
U.S. STOCKS ON THE MOVE-HP, Urban Outfitters, 3D Systems